Research member Dr. Bertrand Routy, postdoctoral student Meriem Messaoudene and their team have published a study in the journal Cancer Discovery showing the anti-cancer benefits of the Brazilian camu-camu berry. Castalagin, a molecule from the Amazonian fruit, increases the effectiveness of immunotherapy by altering the microbiome.

The results of this study will allow clinical trials to begin. Castalagin will be used as an adjunct to drugs in certain cancer patients. 

To read the full story, click here.